Comparison of results after flouroquinolons and combination therapies in type IIIA chronic prostatitis

Basit Öğe Kaydı
dc.authoridözer, ali/0000-0002-7144-4915
dc.authoridCaner, Ediz/0000-0001-9717-1209
dc.authorwosidaltintas, ramazan/AAP-2348-2020
dc.authorwosidözer, ali/ABI-2209-2020
dc.authorwosidCaner, Ediz/H-9473-2018
dc.contributor.authorAltintas, R.
dc.contributor.authorOguz, F.
dc.contributor.authorBeytur, A.
dc.contributor.authorEdiz, C.
dc.contributor.authorGunes, A.
dc.contributor.authorOzer, A.
dc.date.accessioned2024-08-04T20:37:54Z
dc.date.available2024-08-04T20:37:54Z
dc.date.issued2013
dc.departmentİnönü Üniversitesien_US
dc.description.abstractPurpose: We investigated retrospectively the clinical outcomes of the patients with type III inflammatory chronic prostatitis, who were treated with fluoroquinolones with and without an alpha-blocker between 2009-2011. Material and methods: Diagnosis was established with medical history (symptoms presented Longer than 3 months within previous 6 months), physical examination, Meares-Stamey test and the questionnaire of the NIH-CPSI. The responses to the treatment were assessed with uroflowmetry test and the questionnaire of NIH-CPSI at initial and after 4 weeks of the treatment. The patients with incomplete data and treatment and who treated with alpha-blockers and/or antibiotics in the period 4 weeks prior to the therapy started in our clinic and had any surgery of lower urinary tract previously were excluded. The patients were classified under 6 groups; group1 = ciprofloxacin, group2 = ofloxacin, group3 = levofloxacin, group4 = ciprofloxacin+tamsulosin, group5 = ofloxacin+tamsulosin, group 6 = levofloxacin+tamsulosin. Wilcoxon Signed Ranks and Kruskal Wallis test were used for comparison of results. Mann Whitney U test with Bonferroni correction made was used as posthoc (P < .05). Results: The median scores of NIH-CPSI decreased significantly in all groups (P < .05). Levofloxacin reduced the median total scores of NIH-CPSI more than ciprofloxacin and ofloxacin monotherapies. The combination therapies were better than antibiotic therapies alone and best result was obtained in levofloxacin + tamsulosin combination. Conclusion: Tamsulosin + fluoroquinolone (especially tamsulosin + levofloxacin) combinations yielded better results in both NIH-CPSI scores and peak flow rates. (C) 2012 AEU. Published by Elsevier Espana, S.L. All rights reserved.en_US
dc.identifier.doi10.1016/j.acuro.2012.11.018
dc.identifier.endpage624en_US
dc.identifier.issn0210-4806
dc.identifier.issn1699-7980
dc.identifier.issue10en_US
dc.identifier.pmid23768504en_US
dc.identifier.scopus2-s2.0-84886946045en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage619en_US
dc.identifier.urihttps://doi.org/10.1016/j.acuro.2012.11.018
dc.identifier.urihttps://hdl.handle.net/11616/96260
dc.identifier.volume37en_US
dc.identifier.wosWOS:000327054300005en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoesen_US
dc.publisherEne Ediciones Slen_US
dc.relation.ispartofActas Urologicas Espanolasen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectFluoroquinolonesen_US
dc.subjectAlpha blockeren_US
dc.subjectChronic prostatitisen_US
dc.titleComparison of results after flouroquinolons and combination therapies in type IIIA chronic prostatitisen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu